MELA Sciences (MELA) Misses Q2 EPS by 66c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
MELA Sciences Reports Second Quarter 2015 Financial Results
August 13, 2015 4:01 PM EDTHORSHAM, Pa., Aug. 13, 2015 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (NASDAQ: MELA), a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders, today reported financial results for the second quarter ended June 30, 2015.
Second Quarter and Recent Corporate Highlights
XTRAC and VTRAC businesses of PhotoMedex, Inc. purchased on June 22, 2015, for $42.5 million in cash and the assumption of certain business-related liabilities. Installed base of XTRAC systems in the U.S. expands to 664 systems placed, up from 554 at the end of the... More